Seven Exciting CME Events from Chicago


June 1 – June 4, 2018, Chicago, IL

Seven Exciting CME Events from Chicago

Please note that slides are for review only and not to be repurposed or published.

PART 1 — NON-SMALL CELL LUNG CANCER: CASES FROM THE COMMUNITY

Introduction:
Dr Love

MODULE 1:
Long-Term Management of NSCLC in Patients with an Activating EGFR Mutation — Dr Oxnard

MODULE 2:
Recent Treatment Advances for Patients with ALK/ROS1- and BRAF-Positive NSCLC; Other Targets with the Potential to Affect Treatment Decision-Making — Dr Shaw

MODULE 3:
Optimal Integration of Immune Checkpoint Inhibition into Clinical Decision-Making for Patients with Locally Advanced NSCLC — Dr Reck

MODULE 4:
Current Role of Immune Checkpoint Inhibitors in Combination with Chemotherapy and/or Anti-angiogenic Agents in the Treatment of Metastatic Disease — Dr Langer

MODULE 5:
Potential Role of Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies in Combination; Future Directions for Clinical Research — Dr Hellmann

Live Poll Results:
Download

PART 2 — MELANOMA: BREAKFAST WITH THE INVESTIGATORS

Slide Presentation:
Download

PART 3 — GASTROINTESTINAL CANCERS: AN EVENING WITH THE INVESTIGATORS

Slide Presentation:
Download

Live Poll Results:
Download

PART 4 — OVARIAN CANCER: BREAKFAST WITH THE INVESTIGATORS

Slide Presentation:
Download

PART 5 — LYMPHOMA, CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA: BEYOND THE GUIDELINES

Introduction:
Dr Love

MODULE 1:
Induction and Maintenance Therapy for Multiple Myeloma (MM) — Dr Fonseca

MODULE 2:
Management of Relapsed/Refractory (R/R) MM; Novel Strategies Under Active Investigation — Dr Richardson

MODULE 3:
Chronic Lymphocytic Leukemia (CLL) — Dr Davids

MODULE 4:
Hodgkin Lymphoma (HL) — Dr Younes

MODULE 5:
Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Ansell

MODULE 6:
Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) — Dr Sehn

Investigator Survey:
Download

Live Poll Results:
Download

PART 6 — RENAL CELL CARCINOMA: BREAKFAST WITH THE INVESTIGATORS

Slide Presentation:
Download

PART 7 — BREAST CANCER: CONSENSUS OR CONTROVERSY?

Introduction:
Dr Love

MODULE 1:
Optimal Treatment Strategies for Patients with Localized HER2-Positive Breast Cancer (BC) — Dr Hurvitz

MODULE 2:
Current Role of Genomic Assays in the Management of ER-Positive Early BC — Dr Burstein

MODULE 3:
Therapeutic Considerations for Patients with ER-Positive, HER2-Negative Metastatic BC (mBC) — Dr Di Leo

MODULE 4:
Protocol and Nonresearch Decision-Making for Patients with HER2-Positive mBC — Dr Sledge

MODULE 5:
Role of PARP Inhibition in the Management of BC — Dr Robson

MODULE 6:
Immune Checkpoint Inhibitors and Other Emerging Therapeutic Strategies — Dr Rugo

Live Poll Results:
Download